Second-Line Treatment Options in Metastatic NSCLC
At Great Debates Solid Tumors in Miami, Florida, Luis Raez, MD, from Memorial Cancer Institute in Pembroke Pines, Florida, discusses current second-line treatment options for metastatic non-small cell lung cancer without actionable mutations after progression on chemoimmunotherapy.
Despite numerous advances in first-line therapy, docetaxel with or without ramucirumab remains the standard second-line option in current guidelines. Dr Raez highlights emerging agents that have shown promising results in clinical trials and may expand future treatment options.
Source:
Raez L. Treatment after progression on chemoimmunotherapy in lung cancer: Continuing standard cytotoxic therapy vs transitioning to alternative approaches. Presented at Great Debates - Solid Tumors; Miami, Florida. March 14-15, 2026.
